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Abstract
Background. Haemodialysis (HD) catheter-related blood
stream infections are a major cause of morbidity and mor-
tality in patients with acute and chronic renal failure.
Methods. We conducted a randomized, prospective,
double-blinded trial investigating the clinical value of
bismuth-coated non-tunneled HD catheters in patients
in need of temporary short-term vascular access. A
standard catheter (SC) was compared to a surface-modi-
fied, bismuth-film-coated catheter (FCC). After removal
of the catheter for any reason, both arterial and venous
lumina were rinsed and the fluid cultured for detection
of bacterial colony-forming units (CFU). The catheter tip
was placed in a tube containing sterile saline, sonicated
and shortly centrifuged to remove debris (3 min at 1000 g).
The supernatant was cultured and assayed for DNA
content.
Results. Seventy-seven patients in three HD units were
randomized. Thirteen patients suffered from acute renal
failure, 60 patients from chronic renal failure, and four pa-
tients without renal insufficiency were treated with plasma
exchange. The time to catheter removal was not signifi-
cantly different between groups, with a mean of 18.5 ± 2
days for SC and 15.1 ± 2 days for FCC. In most cases, the
reasons for catheter removal were related to no further
need for extracorporeal therapy or establishment of a per-
manent vascular access. Six catheters for SC and four ca-
theters for FCC were removed because of presumed
infection. Bacterial colonization was significantly lower
for coated catheters compared to standard catheters, both
for cultured catheter tips as well as for CFU in rinse fluids
(P < 0.05).
Conclusions. Surface modification with bismuth film re-
duces bacterial colonization of temporary non-tunneled
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modified catheters are justified to further investigate the
effect on catheter-related infections, complications and
costs.
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Introduction
The use of central vein catheters (CVC) for haemodialy-
sis (HD) access is related to significant morbidity and
mortality. In the USA, 70% of patients start HD with a
CVC as the vascular access, and 30% of the prevalent
patients are being dialyzed using a permanent catheter
[1]. The use of CVC is associated with an increased mor-
tality. Foley and colleagues reported that annual mortality
was 26% for patients, and adjusted mortality hazard ratio
was 2.18 with a CVC compared to patients with an ar-
teriovenous (AV) fistula [2]. Results of the HEMO study
indicate that patients with CVC at the start and end of the
observation period have an increased relative mortality
risk of 3.4 compared to patients with AV fistula at both
time points. Patients who switched from CVC to an AV
fistula had a mortality risk of only 1.4 [3]. Thus, the in-
creased mortality risk seems to be directly associated
with the use of CVC. One possible and likely cause of
the increased mortality is infection and sepsis related to
the CVC. Indeed, exit site infection is significantly re-
lated to death by sepsis [4]. Thus, preventing CVC infec-
tion is of utmost importance.
Bismuth is a substance whose antimicrobial effects
have been known for many years. Bismuth inhibits the
growth of both Gram-negative and Gram-positive bacteria
[5–7]. The mechanism of antimicrobial action is not com-
pletely known but involves inhibition of the Escherichia
coli rho transcription termination factor [8] and iron
transport [9]. More importantly, bismuth inhibits biofilm
production by Staphylococci and Pseudomonas species
[5,6]. We therefore evaluated the impact of bismuth-coated
CVC on clinical outcome in patients in need of vascular
access for extracorporeal therapy in a randomized con-
trolled trial.
Materials and methods
The study was conducted in the nephrology departments of three different
clinics (Berlin, Munich and Bottrop). All patients in need of vascular ac-
cess for acute extracorporeal therapy of presumably more than 1 week
duration were eligible for the study. Exclusion criteria were age <18 or
>75 years, known hepatitis B or C, known HIV infection, a positive blood
culture within 10 days before randomization, pregnancy, hospitalization of
more than 14 days, respirator therapy, treatment with antibiotics or par-
ticipation in another clinical study within 30 days before randomization.
Patients were informed by the study coordinators and gave written in-
formedconsent.Thelocalethicscommitteeofallthreeclinicsapprovedthe
study protocol. The study has been registered under ISRCTN 81821807.
End points were catheter survival, i.e. days to removal for any cause as
well as bacterial contamination, DNA content of the catheter segments
and laboratory results such as whole blood count, fibrinogen, antithrom-
bin III and C-reactive protein.
After obtaining written informed consent, patients were randomized
to either standard catheters (SC, GamCath
®, Gambro) or to bismuth-
film-coated catheters (FCC, GamCath Dolphin
® Protect, Gambro). In
order to obtain the Conformité Européene (CE)-sign, the catheters had
been extensively tested with respect to bismuth release and toxicity be-
fore market authorization. The catheters meet the requirements according
to current ISO 10993 (no risk to patient of toxicity from the exposure to
Dolphin Protect
® catheters). Randomization was performed by a list pro-
vided before the start of the study. The patients and clinicians who in-
serted the catheters were blinded to the study group assignment.
Catheters were used according to clinical needs and placed considering
universal hygienic precautions according to the European Best Practice
Guidelines [10]. Between treatments, 30% citrate solution was used as a
locking solution. Before each treatment, blood was obtained for whole
blood count, fibrinogen, antithrombin III and C-reactive protein. These
parameters were measured in the central laboratory of each clinic using
routine methods.
Catheters were removed due to the discretion of the treating physician
either when there was no longer need for extracorporeal therapy, when an
alternative vascular access became available or when infection was sus-
pected on clinical grounds.
After aseptic removal of the catheters, both lumina were flushed with
10 ml of sterile saline, and the effluent fluid was collected and stored at
−20°C. Then, the catheters were cut in three pieces under aseptic condi-
tions and stored at −20°C.
Table 1. Patient characteristics
Standard catheter (n = 39) Bismuth-film-coated catheter (n = 38)
Age 57 ± 2 60.7 ± 2
Gender 63% male 61% male
Diabetes 37% 32%
Plasma exchange 2 2
Renal replacement therapy 37 36
Acute renal failure 5 8
Chronic renal failure 32 28
Days in place (median) 18.5 ± 2.2 (15) 15.1 ± 1.7 (12)
Number of sessions (median) 7.7 ± 1 (7) 6.8 ± 1 (6)
Reason for catheter removal
Suspected infection 6 4
Malfunction 3 2
No further need 12 13
Functioning fistula/graft 14 16
Death 1 0
Others 3 3
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Rinse fluids (10 ml) were filtered through membrane filters (Millipore,
0.45 μm, F4PN04370), and filters were subsequently cultured on sheep
blood agar for 48 h at 36°C. The catheter tips (app. 2 cm) were placed
in 10 ml of sterile saline and subjected to ultrasound sonication for 2 min
at 35 kHz (Dentil, SonoRex RK100 H). The fluid supernatant was then
filtered as described above, and filters were cultured on sheep blood agar
for 48 h at 36°C. Colony-forming units (CFU) were counted and charac-
terized with standard microbiological methods.
Detection of oligonucleotides
For detection of DNA sticking to the catheter surface, the tip of the ca-
theters as described above as well as the next 2-cm piece (called shaft
piece) were cut and placed in Tris–EDTA buffer (10 mM Tris, 1 mM
EDTA pH 7.5). The catheter pieces were subjected to sonication for 30
min and the buffer then assayed for oligonucleotides (ODN). ODN were
detected using the Quant-it OliGreen kit (Molecular Probes, Eugene, OR,
USA) that labels ODN with a fluorescent dye and subsequently detects
the bound amount of dye using a FLUOtest Optima fluorescent plate
reader. The test was performed as described by the manufacturer; the sen-
sitivity of the assay was 1.2 ng/ml.
Statistics
Catheter survival was analyzed by Kaplan–Meier analysis (log rank Man-
tel–Cox test). Microbiological results for the catheter tip segments were
compared using the chi-square test. Microbiological results in rinse fluids
from both (arterial and venous) lumina were combined and also compared
using the chi-square test. The DNA content was compared using the
Mann–Whitney test for unpaired, nonparametric samples. Data are given
as means ± SEM or median and range as indicated.
Results
A total of 103 patients were randomized (53 for SC and 50
for FCC). Results could be analyzed for 77 patients; 26 pa-
Fig. 1. (A) Number of catheters removed for suspected infection/thrombosis. (B) Number of direct catheters with bacterial cultures >100 CFU. (C)
Number of catheters with rinse fluids containing >100 CFU/ml. P < 0.05 denotes significance between groups; n.s., not significant.
Fig. 2. CFU of the cultured segments of FCC and SC catheters.
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1), loss to follow-up (n = 1) and failure of collecting cath-
eter and rinse fluid samples (n = 24). Samples were not col-
lected mainly when catheters were removed during the
night shift or when samples thawed before/during transport.
Table 1 gives the demographic details of the patient
population. Two in each group received catheters for
plasma exchange, the remaining patients for renal replace-
ment therapy. Of these, the minority had acute renal fail-
ure, while the majority had decompensated chronic renal
failure or were chronic HD patients with temporary failure
of their usual vascular access.
Catheter survival was not significantly different between
groups, mean 18.2 ± 2 days for SC and 15.1 ± 2 days for
FCC (n.s., Table 1). The number of extracorporeal treat-
ments was also not significantly different between groups
(Table 1). In most cases, the reason for catheter removal
was not related to infection (six patients with SC and four
patients with FCC) but rather to no further need for extra-
corporeal therapy (11 and 14, respectively), malfunction
(three vs. two) or establishment of an AV fistula or a pros-
thetic graft for vascular access (14 and 16 patients, respect-
ively, Table 1 and Figure 1). The Kaplan–Meier analysis
for catheter survival was not significant different between
groups.
Bacterial colonization of the catheter tip was higher in
SC compared to FCC [mean ± SEM; median (range) 63 ±
29 CFU; 0 (0–600) for SC vs. 3.5 ± 1.6 CFU; 0 (0–60) for
FCC, P < 0.001, Figures 1 and 2]. The number of CFU in
10 ml rinse fluid was also significantly higher in SC com-
pared to FCC [39 ± 13; 0 (0–500) for SC vs. 9.2 ± 6; 0 (0–
500) for FCC, P = 0.04, Figures 1 and 3]. Characterization
of the bacterial strains revealed mostly coagulase-negative
Staphylococci (total number for all positive samples n =
76), the incidence of other strains was much lower (two
Streptococci; one Acinetobacter; two Micrococci; one E.
coli, two Corynebacter).
The DNA content of the catheter tip and adjacent shaft
segments was not significantly different between groups
(Figure 4). The median DNA content for catheter tips
was 0.81 ng/ml for SC and 0.89 ng/ml for FCC; for cath-
eter shaft the median was 1.39 ng/ml for SC and 1.2 ng/ml
for FCC (Figure 4, n.s).
There were no overall differences between groups re-
garding leukocyte count, fibrinogen and antithrombin III.
However, when the course of C-reactive protein (CRP) was
analyzed during the study, there was a significant trend for
CRP to decrease in patients with FCC catheters and a trend
to increase in patients with SC. The difference in CRP be-
tween the last and the first extracorporeal treatment was
significantly lower for FCC compared to SC (median
−0.2 mg/dl for FCC and +0.17 mg/dl for SC, P = 0.03,
Figure 5).
Fig. 5. Median difference in CRP between the first and the last treatment
with the assigned catheter. The range of the differences was for FCC, −20
to +2.7; and for SC, −4 to +11 mg/dl.
Fig. 4. Boxplots of the DNA content of tip or shaft segments of FCC and
SC catheters.
Fig. 3. Number of CFU in 10 ml rinse fluids for FCC and SC catheters.
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In the present study, catheter survival was not different
between coated and standard catheters. On the other
hand, the secondary end point bacterial colonization was
significantly lower for coated catheters compared to stand-
ard catheters indicating that bismuth coating of catheters
was effective. The reason why less bacterial colonization
did not translate into the clinical end point of catheter sur-
vival was the non-anticipated relatively short duration of
catheter requirement in the present study. The mean dur-
ation of catheters in place was 18 and 15 days, respectively.
Most patients received a catheter for acute malfunction of
theirusualvascularaccessorforacuterenalfailure;removal
of catheters was mostly related to no further need instead of
infections. Thus, the advantages of bismuth-film-coated ca-
theters regarding colonization likely did not have enough
time to turn into improved catheter survival. Indeed, when
comparing tunneled and non-tunneled catheters, a differ-
ence in catheter survival was evident only at 2 weeks
and later after catheter insertion [11]. In another study
comparing different lock solutions, the difference in cath-
eter survival was only evident after 50 days and later [12].
The present study demonstrates advantages of bismuth-
coated catheters regarding bacterial colonization; further
trials are warranted in patients with longer requirement of
catheters to establish the benefits of coated catheters on
catheter survival, morbidity and costs. In addition, bismuth
has potential toxic effects such as cytotoxicity or neurotox-
icity [13] that may only be observed after treating a larger
population. However, the total amounts of bismuth on the
catheter surface is very low; we did not observe local reac-
tions, and bismuth inhibits bacterial growth substantially at
concentrations well below the toxic threshold in tissue
culture [7].
Central venous catheters are widely used as vascular ac-
cess. Data from the DOPPS study indicate that in Ger-
many, 25% of incident HD patients start dialysis with
catheters, while in other countries the use of catheters
is even more common (France 40%, USA 70%). During
recent years, the use of catheters in prevalent HD patients
has even increased further [1]. Catheter-related blood
stream infections are a significant cause for mortality in
patients in intensive care units with up to 35% mortality
[14]. Besides increasing mortality, catheter-related infec-
tions are associated with additional costs. It was calculated
that one episode of catheter-related blood stream infections
increases hospital expenditure between $11 000 and
$54 000 [15,16]. Thus, preventing catheter-related infec-
tions is of enormous clinical importance.
There are several options to prevent catheter infections.
The use of antibiotics or bactericidal substances in lock
solutions is more effective than heparin alone to prevent
infections [12,17]. The implementation of simple but
strict standards for catheter placement and care signifi-
cantly decreases catheter-related infections [15]. The
present study indicates that the use of bismuth-coated
catheters decreases bacterial colonization of HD catheters
and may prevent potentially lethal catheter-related blood
stream infections.
In the present study, many subjects (26 of 103) had to
be excluded from analysis. Reasons for exclusion were
mainly due to failure of proper catheter preservation/col-
lection after removal. This large number was not antici-
pated and may have been caused by the complex
procedure of catheter collection. However, exclusion oc-
curred equally in all three participating centers and was
equally distributed in both groups. We therefore do not
consider exclusion of subjects as a major bias influencing
our results.
A proposed strategy to reduce catheter-related blood
stream infections catheter-related blood stream infections
is the use of catheters impregnated or coated with anti-
microbial substances such as chlorhexidine, bismuth, plat-
inum and silver sulfadiazine or the antibiotics cefazolin or
minocycline and rifampicin (for review, see [18]). A num-
ber of studies during the last two decades are available on
the effectiveness of antimicrobial catheters in preventing
catheter-relatedbloodstreaminfectionsandshowthatexter-
nally coated chlorhexidine–silver catheters significantly
reduce the risk of catheter-related blood stream infections
in the intensive care unit [19]. In a study on silver-
coated, tunneled HD catheters, Trerotola et al. reported
slightly but not significantly lower infection and coloni-
zation rates compared to uncoated catheters [20]. Minocy-
cline–rifampicin-coated catheters appear to be even more
effective in preventing catheter-related blood stream infec-
tions. Despite these studies, coated catheters are not com-
monly used. There are reservations about the quality of
the trial evidence, e.g. most studies were not blinded and
were driven by manufacturers [21]. In addition, all studies
used either catheter colonization or catheter-related blood
stream infections as end points; none of these studies inves-
tigated hard clinical end points such as mortality, length of
hospital stay etc. Other factors related to cost, toxicity
and increased microbial resistance prevented the recom-
mendation for these catheters. Also, the use of these de-
vices may divert resources needed to implement other
evidence-based preventive measures that are more likely
to be effective than coated catheters [15].
Our study demonstrated significant differences in cath-
etercolonizationbetweenanoncoatedandabismuth-coated
catheter in a clinical setting. We did not choose mortality as
an end point because a much larger number of subjects
would havebeen needed to demonstrate a significant differ-
ence in mortality. However, the present study was rando-
mized, prospective and fully blinded to both patients and
participant physicians. Thus, the design was superior to
most previous studies on coated catheters. It is also one of
the first studies in patientsin need of extracorporeal therapy
exclusivelyandthefirstoneusingbismuth-coatedcatheters.
We could demonstrate that bismuth coating of central vein
catheters for HD reduces bacterial colonization without
showing signs of adverse events. Bismuth-coated catheters
may not eliminate the problem of catheter-related blood
stream infections but at least improve its rate. Given the
great importance of CVC infections for both prevalent and
incidentHDpatients,furtherandlargertrialsmayprovethat
Bismuth-coatedcathetersmaycontributetolowermorbidity
and possibly mortality of HD patients.
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Abstract
Background. The incidence of congestive heart failure is
3-fold greater than that of acute coronary syndrome in
haemodialysis (HD) patients. The purpose of this study
was to determine if blood flow through an arteriovenous
(AV) access contributes to an increase in left ventricular
mass (LVM) that may increase the risk of congestive
heart failure.
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